Peptide Comparison
VesilutevsCerebrolysin
Tissue-specific dipeptide bioregulator (Glu-Asp) that epigenetically normalizes urogenital function through chromatin remodeling, anti-inflammatory cytokine regulation, and smooth muscle tone restoration in the bladder and prostate
Porcine brain-derived neuropeptide preparation containing bioactive peptide fragments of neurotrophic factors, used clinically in over 40 countries for stroke recovery, traumatic brain injury, and cognitive impairment
At a Glance
Quick
comparison
Dose Range
Vesilute
20–40 mg
Cerebrolysin
5–50 ml
Frequency
Vesilute
Once daily
Cerebrolysin
Once daily
Administration
Vesilute
Oral (capsule/tablet)
Cerebrolysin
Intravenous (IV) injection or infusion
Cycle Length
Vesilute
12+ weeks
Cerebrolysin
8-12 weeks
Onset Speed
Vesilute
Gradual (3-4 weeks)
Cerebrolysin
Moderate (1-2 weeks)
Evidence Level
Vesilute
Moderate human trials (Phase 1-2)
Cerebrolysin
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Bladder Health
Prostate Support
Tissue Repair
Stroke Recovery
Alzheimer's Support
Brain Injury Healing
Technical Data
Compound
specifications
Vesilute
Molecular Formula
C9H14N2O7
Molecular Weight
262.2 g/mol
Half-Life
Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids via standard pathways
Bioavailability
High oral bioavailability for a dipeptide — absorbed intact by intestinal peptide transporter PepT1 (SLC15A1); ultra-short structure enables efficient cellular uptake and nuclear penetration
CAS Number
3918-84-1
Cerebrolysin
Molecular Formula
Complex mixture — no single molecular formula (contains multiple peptide fragments and free amino acids derived from porcine brain proteins)
Molecular Weight
Bioactive peptide components are all below 10 kDa (10,000 Da); the preparation contains a spectrum of peptide sizes
Half-Life
Approximately 15-30 minutes (IV administration)
Bioavailability
~85-100% (intramuscular injection)
CAS Number
Not assigned (biological mixture)
Protocols
Dosing
tiers
Vesilute
Cerebrolysin
Applications
Best
suited for
Vesilute
Supporting bladder health and urinary function in aging individuals
Vesilute is particularly well-suited for individuals focused on supporting bladder health and urinary function in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Bioregulatory approach to benign prostatic hyperplasia (BPH) management
Vesilute is particularly well-suited for individuals focused on bioregulatory approach to benign prostatic hyperplasia (bph) management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic urogenital inflammation through epigenetic mechanisms
Vesilute is particularly well-suited for individuals focused on reducing chronic urogenital inflammation through epigenetic mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing standard urological treatments with peptide bioregulator therapy
Vesilute is particularly well-suited for individuals focused on complementing standard urological treatments with peptide bioregulator therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cerebrolysin
Post-stroke neurorecovery and rehabilitation support
Cerebrolysin is particularly well-suited for individuals focused on post-stroke neurorecovery and rehabilitation support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cognitive support in Alzheimer's disease and vascular dementia
Cerebrolysin is particularly well-suited for individuals focused on cognitive support in alzheimer's disease and vascular dementia. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Traumatic brain injury recovery and neuroprotection
Cerebrolysin is particularly well-suited for individuals focused on traumatic brain injury recovery and neuroprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Age-related cognitive decline and mild cognitive impairment
Cerebrolysin is particularly well-suited for individuals focused on age-related cognitive decline and mild cognitive impairment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Vesilute
Common
- Mild gastrointestinal discomfort
- Increased urinary frequency initially
- Mild headache
- Minor fatigue
Uncommon
- Injection site irritation
Serious
- No documented serious adverse effects
Cerebrolysin
Common
- Injection site reactions
- Headache
- Dizziness and vertigo
- Nausea and gastrointestinal discomfort
- Agitation or restlessness
- Fever
Uncommon
- Allergic reaction
Serious
- Severe hypersensitivity reaction
Research Status
Safety
& evidence
Vesilute
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Vesilute (fibroin-derived peptide from Bombyx mori silk) demonstrates favorable biocompatibility from cosmetic ingredient testing with minimal allergic or irritant potential despite its animal protein origin. Limited systemic absorption occurs topically, confining effects to dermal layers with low risk of systemic toxicity. Silk-derived peptides have been used in cosmetics for >20 years without documented serious adverse events in published literature. Theoretical hypersensitivity risk exists for individuals with silk allergy, though cross-reactivity with purified peptide is low.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive urinary tract infection requiring antibiotic treatment — treat infection first
- xBladder or prostate malignancy — proliferative effects of peptide bioregulators may be contraindicated
Cerebrolysin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Cerebrolysin is an FDA-unregulated neuroprotective agent consisting of porcine brain-derived peptides and amino acids that has been used primarily in Eastern Europe and Asia. Safety data is limited to observational clinical use and small open-label trials rather than rigorous randomized controlled trials with formal safety monitoring. As a complex mixture of undefined peptide fragments from animal sources, batch consistency and sterility cannot be guaranteed without pharmaceutical manufacturing standards. Potential allergic reactions to porcine proteins and transmissible spongiform encephalopathy (TSE) risks from animal-derived components have not been adequately ruled out.
Contraindications
- xKnown hypersensitivity to Cerebrolysin or porcine-derived products
- xSevere renal impairment or renal failure
- xStatus epilepticus or uncontrolled epilepsy
- xPregnancy and breastfeeding — insufficient safety data
Decision Guide
Which is
right for you?
Choose Vesilute if...
- Supporting bladder health and urinary function in aging individuals
- Bioregulatory approach to benign prostatic hyperplasia (BPH) management
- Reducing chronic urogenital inflammation through epigenetic mechanisms
- Complementing standard urological treatments with peptide bioregulator therapy
Choose Cerebrolysin if...
- Post-stroke neurorecovery and rehabilitation support
- Cognitive support in Alzheimer's disease and vascular dementia
- Traumatic brain injury recovery and neuroprotection
- Age-related cognitive decline and mild cognitive impairment